Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases

被引：63

作者：

Sehon, Clark A. ^{[1
]}

Wang, Gren Z. ^{[1
]}

Viet, Andrew Q. ^{[1
]}

Goodman, Krista B. ^{[1
]}

Dowdell, Sarah E. ^{[1
]}

Elkins, Patricia A. ^{[3
]}

Semus, Simon F. ^{[3
]}

Evans, Christopher ^{[2
]}

Jolivette, Larry J. ^{[2
]}

Kirkpatrick, Robert B. ^{[4
]}

Dul, Edward ^{[4
]}

Khandekar, Sanjay S. ^{[4
]}

Yi, Tracey ^{[4
]}

Wright, Lois L. ^{[5
]}

Srnith, Gary K. ^{[5
]}

Behm, David J. ^{[6
]}

Bentley, Ross ^{[7
]}

Doe, Christopher P. ^{[7
]}

Hu, Erding ^{[6
]}

Lee, Dennis ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Dept Med Chem, King Of Prussia, PA 19406 USA

[2] GlaxoSmithKline Inc, Dept Drug Metab & Pharmacokinet, King Of Prussia, PA 19406 USA

[3] GlaxoSmithKline Inc, CVU CEDD, Dept Computat & Struct Sci, King Of Prussia, PA 19406 USA

[4] GlaxoSmithKline Inc, Dept Gene Express & Prot Biochem, King Of Prussia, PA 19406 USA

[5] GlaxoSmithKline Inc, Dept Assay Dev & Compound Profiling, Res Triangle Pk, NC 27709 USA

[6] GlaxoSmithKline Inc, Dept Vasc Biol, King Of Prussia, PA 19406 USA

[7] GlaxoSmithKline Inc, Dept Investigat Biol, King Of Prussia, PA 19406 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 51卷 / 21期

关键词：

D O I：

10.1021/jm8005096

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of this enzyme in many aspects of cardiovascular function. Here we report a series of ROCK 1 inhibitors which were originally derived from a dihydropyrimidinone core 1. Our efforts focused oil the optimization of dihydropyrimidine 2. which resulted in the identification of a series of dihydropyrimidines with improved pharmacokinetics and P450 properties.

引用

页码：6631 / 6634

页数：4

共 50 条

[1] Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases
Hirooka Y.
Shimokawa H.
American Journal of Cardiovascular Drugs, 2005, 5 (1) : 31 - 39
[2] Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential
Feng, Yangbo
LoGrasso, Philip V.
Defert, Olivier
Li, Rongshi
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (06) : 2269 - 2300
[3] The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents
DeNinno, Michael P.
Andrews, Melissa
Bell, Andrew S.
Chen, Yue
Eller-Zarbo, Cynthia
Eshelby, Nan
Etienne, John B.
Moore, Dianna E.
Palmer, Michael J.
Visser, Michael S.
Yu, Li J.
Zavadoski, William J.
Gibbs, E. Michael
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (09) : 2537 - 2541
[4] Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase
Prime, Michael E.
Courtney, Stephen M.
Brookfield, Frederick A.
Marston, Richard W.
Walker, Victoria
Warne, Justin
Boyd, Andrew E.
Kairies, Norman A.
von der Saal, Wolfgang
Limberg, Anja
Georges, Guy
Engh, Richard A.
Goller, Bernhard
Rueger, Petra
Rueth, Matthias
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (01) : 312 - 319
[5] Optimisation of a series of potent, selective and orally bioavailable GlyT1 inhibitors
Thomson, Joanne L.
Blackaby, Wesley P.
Jennings, Andrew S. R.
Goodacre, Simon C.
Pike, Andrew
Thomas, Steve
Brown, Terry A.
Smith, Alison
Pillai, Gopalan
Street, Leslie J.
Lewis, Richard T.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) : 2235 - 2239
[6] Discovery and optimization of potent, selective, and orally bioavailable Jak1 inhibitors
Zak, Mark
Johnson, Adam
Van Abbema, Anne
Waszkowycz, Bohdan
Eigenbrot, Charles
Chang, Christine
Hurley, Christopher
Hanan, Emily
Kenny, Jane
Kulagowski, Janusz
DeVoss, Jason
Murray, Jeremy
Balazs, Mercedesz
Steffek, Micah
Koehler, Michael
Ghilardi, Nico
Chakravarty, Paroma
Lupardus, Patrick
Gibbons, Paul
Dragovich, Peter
Bergeron, Philippe
Pulk, Rebecca
Mendonca, Rohan
Savage, Scott
Labadie, Sharada
Gradl, Stefan
Ward, Stuart
Blair, Wade
Jia, Wei
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[7] Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: Potential agents for treatment of erectile dysfunction
Yu, GX
Mason, H
Wu, XM
Wang, J
Chong, SH
Beyer, B
Henwood, A
Pongrac, R
Seliger, L
He, B
Normandin, D
Ferrer, P
Zhang, RG
Adam, L
Humphrey, WG
Krupinski, J
Macor, JE
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (04) : 457 - 460
[8] Development of indazole Rho-kinase (ROCK 1) inhibitors as potential antihypertensive agents
Goodman, Krista Beaver
Dowdell, Sarah E.
Gaitanopoulos, Dimitri E.
Ivy, Robert
Sehon, Clark
Stavenger, Robert
Wang, Gren
Viet, Andrew Q.
Xu, Weiwei
Ye, Guosen
Semus, Simon F.
Evans, Christopher
Fries, Harvey E.
Jolivette, Larry J.
Jung, David K.
Wright, Lois L.
Smith, Gary K.
Behm, David J.
Bentley, Ross
Doe, Christopher P.
Hu, Erding
Lee, Dennis
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
[9] Discovery of potent, selective, orally bioavailable Stearoyl-CoA desaturase 1 inhibitors
Liu, Gang
Lynch, John K.
Freeman, Jennifer
Liu, Bo
Xin, Zhili
Zhao, Hongyu
Serby, Michael D.
Kym, Philip R.
Suhar, Tom S.
Smith, Harriet T.
Cao, Ning
Yang, Ruojing
Janis, Rich S.
Krauser, Joel A.
Cepa, Steven P.
Beno, David W. A.
Sham, Hing L.
Collins, Christine A.
Surowy, Teresa K.
Camp, Heidi S.
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (13) : 3086 - 3100
[10] Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4
Wang, Zhulun
Sun, Daqing
Johnstone, Sheree
Cao, Zhaodan
Gao, Xiong
Jaen, Juan C.
Liu, Jingqian
Lively, Sarah
Miao, Shichang
Sudom, Athena
Tomooka, Craig
Walker, Nigel P. C.
Wright, Matthew
Yan, Xuelei
Ye, Qiuping
Powers, Jay P.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (23) : 5546 - 5550

← 1 2 3 4 5 →